{"id":23173,"date":"2023-01-04T15:59:00","date_gmt":"2023-01-04T07:59:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23173"},"modified":"2025-01-26T16:02:53","modified_gmt":"2025-01-26T08:02:53","slug":"sihuans-hui-sheng-bio-completes-series-a-financing-for-diabetes-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23173","title":{"rendered":"Sihuan’s Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline"},"content":{"rendered":"\n

China – based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460<\/a>) has announced the successful completion of a Series A + financing round for its subsidiary Hui Sheng Bio – pharmaceutical Co., Ltd. The funding round was led by Jilin Baixing Bairong Investment Center, with additional contributions from Jilin Province Private Equity Co., Ltd, Jilin Province Technology Investment Fund Co., Ltd, and Wuxi Shangwei Venture Capital Partnership.<\/p>\n\n\n\n

Financing Details and Future Plans<\/strong>
The Series A + financing raised a total of RMB 580 million (USD 84 million), valuing Hui Sheng Bio at RMB 5.58 billion (USD 808.83 million). Sihuan retains a 61.29% stake in Hui Sheng Bio. The proceeds from the financing will be used for product promotion, clinical studies, and supplementary working capital. This strategic funding aims to accelerate the development and commercialization of Hui Sheng Bio’s robust diabetes pipeline.<\/p>\n\n\n\n

Focus on Diabetes and Pipeline Highlights<\/strong>
Hui Sheng Bio is focused on the diabetes market, with over 40 products in its pipeline. These include second – , third – , and fourth – generation insulins and analogs (such as basic, pre – mixed, and fast – acting products), as well as molecules targeting SGLT – 2 and GLP – 1 receptors. The comprehensive pipeline positions Hui Sheng Bio to address significant unmet medical needs in diabetes management and treatment.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China – based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[39,20,930,146],"class_list":["post-23173","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-diabetes","tag-finance","tag-hkg-0460","tag-sihuan-pharmaceutical"],"yoast_head":"\nSihuan's Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China - based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion of a Series A + financing round for its subsidiary Hui Sheng Bio - pharmaceutical Co., Ltd. The funding round was led by Jilin Baixing Bairong Investment Center, with additional contributions from Jilin Province Private Equity Co., Ltd, Jilin Province Technology Investment Fund Co., Ltd, and Wuxi Shangwei Venture Capital Partnership.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23173\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sihuan's Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23173\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-04T07:59:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-26T08:02:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23173#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23173\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sihuan’s Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline\",\"datePublished\":\"2023-01-04T07:59:00+00:00\",\"dateModified\":\"2025-01-26T08:02:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23173\"},\"wordCount\":223,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Diabetes\",\"Finance\",\"HKG: 0460\",\"Sihuan Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23173#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23173\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23173\",\"name\":\"Sihuan's Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-01-04T07:59:00+00:00\",\"dateModified\":\"2025-01-26T08:02:53+00:00\",\"description\":\"China - based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion of a Series A + financing round for its subsidiary Hui Sheng Bio - pharmaceutical Co., Ltd. The funding round was led by Jilin Baixing Bairong Investment Center, with additional contributions from Jilin Province Private Equity Co., Ltd, Jilin Province Technology Investment Fund Co., Ltd, and Wuxi Shangwei Venture Capital Partnership.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23173#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23173\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23173#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sihuan’s Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sihuan's Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline - Insight, China's Pharmaceutical Industry","description":"China - based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion of a Series A + financing round for its subsidiary Hui Sheng Bio - pharmaceutical Co., Ltd. The funding round was led by Jilin Baixing Bairong Investment Center, with additional contributions from Jilin Province Private Equity Co., Ltd, Jilin Province Technology Investment Fund Co., Ltd, and Wuxi Shangwei Venture Capital Partnership.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23173","og_locale":"en_US","og_type":"article","og_title":"Sihuan's Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23173","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-01-04T07:59:00+00:00","article_modified_time":"2025-01-26T08:02:53+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23173#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23173"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sihuan’s Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline","datePublished":"2023-01-04T07:59:00+00:00","dateModified":"2025-01-26T08:02:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23173"},"wordCount":223,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Diabetes","Finance","HKG: 0460","Sihuan Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23173#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23173","url":"https:\/\/flcube.com\/?p=23173","name":"Sihuan's Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-01-04T07:59:00+00:00","dateModified":"2025-01-26T08:02:53+00:00","description":"China - based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion of a Series A + financing round for its subsidiary Hui Sheng Bio - pharmaceutical Co., Ltd. The funding round was led by Jilin Baixing Bairong Investment Center, with additional contributions from Jilin Province Private Equity Co., Ltd, Jilin Province Technology Investment Fund Co., Ltd, and Wuxi Shangwei Venture Capital Partnership.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23173#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23173"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23173#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sihuan’s Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23173"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23173\/revisions"}],"predecessor-version":[{"id":23174,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23173\/revisions\/23174"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}